Manufacturers report positive results for dupilumab in Phase III paediatric asthma study
In a phase III study in patients aged six to 11 with uncontrolled moderate-to-severe asthma, dupilumab participants experienced a significant reduction in the rate of severe asthma attacks over one year vs placebo.
Source:
PharmaTimes